Receptor for advanced glycation end products gene polymorphisms in cardiac syndrome X

Önal,Burak; Özen,Deniz; Demir,Bülent; Akkan,Ahmet  G.; Özyazgan,Sibel

doi:10.3892/br.2019.1231

Receptor for advanced glycation end products gene polymorphisms in cardiac syndrome X

Authors:
- Burak Önal
- Deniz Özen
- Bülent Demir
- Ahmet G. Akkan
- Sibel Özyazgan
View Affiliations

Affiliations: Department of Medical Pharmacology, Faculty of Medicine, Biruni University, Istanbul 34010, Turkey, Department of Medical Pharmacology, Cerrahpaşa Medical Faculty, Istanbul University‑Cerrahpaşa, Istanbul 34096, Turkey, Department of Cardiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul 34147, Turkey
Published online on: July 22, 2019 https://doi.org/10.3892/br.2019.1231
Pages: 123-129

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endothelial and microvascular dysfunction serve important roles in the formation and pathogenesis of cardiac syndrome X (CSX). Expression of receptor for advanced glycation end products (RAGE) is suggested to be increased in several conditions, including diabetes, inflammation and vascular diseases. In the present study, RAGE gene polymorphisms in patients with CSX and healthy controls were investigated. A total of 114 patients, diagnosed with CSX using coronary angiography results following complaints of angina and objective ischemia, and 103 healthy controls participated in the study. Whether there was a difference in genotype distributions of RAGE gene ‑374T/A, ‑429T/C and Glys82Ser polymorphisms between patients with CSX and healthy controls was investigated. Following DNA isolation from blood samples of the participants, the polymorphic regions were examined by quantitative polymerase chain reaction, and the genotyping results were statistically analyzed. When the genotypic distributions of ‑374T/A, ‑429T/C and Gly82Ser polymorphisms were investigated in patients with CSX and healthy controls, no statistically significant differences were identified between the two groups (P>0.05). Likewise, no statistically significant differences were observed in the allelic distributions of all 3 polymorphic regions (P>0.05). To the best of our knowledge, the present study also investigated the association between CSX and RAGE gene polymorphisms for the first time. No statistically significant differences in RAGE gene polymorphisms between the CSX and control groups were observed. We hypothesized that significant results may be obtained by increasing the numbers of patients and healthy controls in future studies.

View Figures

View References

1	Singh M, Singh S, Arora R and Khosla S: Cardiac syndrome X: Current concepts. Int J Cardiol. 142:113–119. 2010.PubMed/NCBI View Article : Google Scholar
2	Vermeltfoort IA, Raijmakers PG, Riphagen II, Odekerken DA, Kuijper AF, Zwijnenburg A and Teule GJ: Definitions and incidence of cardiac syndrome X: Review and analysis of clinical data. Clin Res Cardiol. 99:475–481. 2010.PubMed/NCBI View Article : Google Scholar
3	Rasmi Y, Raeisi S and Seyyed Mohammadzad MH: Association of inflammation and cytotoxin-associated gene a positive strains of helicobacter pylori in cardiac syndrome X. Helicobacter. 17:116–120. 2012.PubMed/NCBI View Article : Google Scholar
4	Agrawal S, Mehta PK and Bairey Merz CN: Cardiac syndrome X: Update 2014. Cardiol Clin. 32:463–478. 2014.PubMed/NCBI View Article : Google Scholar
5	Zuchi C, Tritto I and Ambrosio G: Angina pectoris in women: Focus on microvascular disease. Int J Cardiol. 163:132–140. 2013.PubMed/NCBI View Article : Google Scholar
6	Laksanakorn W, Laprattanagul T, Wei J, Shufelt C, Minissian M, Mehta PK and Merz CNB: Cardiac rehabilitation for cardiac syndrome X and microvascular angina: A case report. Int J Case Rep Images. 6:239–244. 2015. View Article : Google Scholar
7	Lanza GA and Crea F: Primary coronary microvascular dysfunction: Clinical presentation, pathophysiology, and management. Circulation. 121:2317–2325. 2010.PubMed/NCBI View Article : Google Scholar
8	Lanza GA, Sestito A, Cammarota G, Grillo RL, Vecile E, Cianci R, Speziale D, Dobrina A, Maseri A and Crea F: Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am J Cardiol. 94:40–44. 2004.PubMed/NCBI View Article : Google Scholar
9	Cosín-Sales J, Pizzi C, Brown S and Kaski JC: C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol. 41:1468–1474. 2003.PubMed/NCBI View Article : Google Scholar
10	Dollard J, Kearney P, Clarke G, Moloney G, Cryan JF and Dinan TG: A prospective study of C-reactive protein as a state marker in Cardiac Syndrome X. Brain Behav Immun. 43:27–32. 2015.PubMed/NCBI View Article : Google Scholar
11	Yang S, Wang H, Yang Y, Wang W, Jiang J, Zhao X, Du Q, Wang X, Yao Y, Shen H, et al: Association study of AGER gene polymorphism and hypertension in Han Chinese population. Gene. 498:311–316. 2012.PubMed/NCBI View Article : Google Scholar
12	Kamide T, Kitao Y, Takeichi T, Okada A, Mohri H, Schmidt AM, Kawano T, Munesue S, Yamamoto Y, Yamamoto H, et al: RAGE mediates vascular injury and inflammation after global cerebral ischemia. Neurochem Int. 60:220–228. 2012.PubMed/NCBI View Article : Google Scholar
13	Kawai T, Kamide K, Ito N, Onishi M, Oguro R, Takeya Y, Tatara Y, Maekawa Y, Katsuya T, Ohishi M and Rakugi H: -374 T/A polymorphism in RAGE gene is associated with onset of diabetes mellitus, atherosclerosis, and renal dysfunction in patients with hypertension. Clin Exp Hypertens. 35:236–241. 2013.PubMed/NCBI View Article : Google Scholar
14	Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, et al: Receptor for advanced-glycation end products: Key modulator of myocardial ischemic injury. Circulation. 113:1226–1234. 2006.PubMed/NCBI View Article : Google Scholar
15	Kalousová M, Brabcová I, Germanová A, Jáchymová M, Matl I, Mestek O, Bandúr S, Zima T and Viklický O: RAGE polymorphisms, renal function and histological finding at 12 months after renal transplantation. Clin Biochem. 42:347–352. 2009.PubMed/NCBI View Article : Google Scholar
16	Ng ZX, Kuppusamy UR, Iqbal T and Chua KH: Receptor for advanced glycation end-product (RAGE) gene polymorphism 2245G/A is associated with pro-inflammatory, oxidative-glycation markers and sRAGE in diabetic retinopathy. Gene. 521:227–233. 2013.PubMed/NCBI View Article : Google Scholar
17	Liu L and Qiu XB: Association between the receptor for advanced glycation end products gene polymorphisms and coronary artery disease. Mol Biol Rep. 40:6097–6105. 2013.PubMed/NCBI View Article : Google Scholar
18	Cui X, Chen H, Hou X, Wang S, Jayaram S and Zheng Z: Polymorphism of the RAGE affects the serum inflammatory levels and risk of ischemic stroke in a Chinese population. Cell Physiol Biochem. 32:986–996. 2013.PubMed/NCBI View Article : Google Scholar
19	Falcone C, Campo I, Emanuele E, Buzzi MP, Zorzetto M, Sbarsi I and Cuccia M: Relationship between the -374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med. 14:1061–1064. 2004.PubMed/NCBI View Article : Google Scholar
20	Gao J, Shao Y, Lai W, Ren H and Xu D: Association of polymorphisms in the RAGE gene with serum CRP levels and coronary artery disease in the Chinese Han population. J Hum Genet. 55:668–675. 2010.PubMed/NCBI View Article : Google Scholar
21	Tripathi AK, Chawla D, Bansal S, Banerjee BD, Madhu SV and Kalra OP: Association of RAGE gene polymorphism with vascular complications in Indian type 2 diabetes mellitus patients. Diabetes Res Clin Pract. 103:474–481. 2014.PubMed/NCBI View Article : Google Scholar
22	Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, et al: Guidelines on the management of stable angina pectoris: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 27:1341–1381. 2006.PubMed/NCBI View Article : Google Scholar
23	D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM and Kannel WB: General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. 117:743–753. 2008.PubMed/NCBI View Article : Google Scholar
24	Bruce RA: Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res. 3:323–332. 1971.PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
26	Tousoulis D, Davies GJ, Asimakopoulos G, Homaei H, Zouridakis E, Ahmed N and Kaski JC: Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol. 24:301–304. 2001.PubMed/NCBI View Article : Google Scholar
27	Asbury EA and Collins P: Cardiac syndrome X. Int J Clin Pract. 59:1063–1069. 2005.PubMed/NCBI View Article : Google Scholar
28	Arroyo-Espliguero R, Mollichelli N, Avanzas P, Zouridakis E, Newey VR, Nassiri DK and Kaski JC: Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J. 24:2006–2011. 2003.PubMed/NCBI View Article : Google Scholar
29	Arroyo-Espliguero R and Kaski JC: Microvascular dysfunction in cardiac syndrome X: The role of inflammation. CMAJ. 174(1833)2006.PubMed/NCBI View Article : Google Scholar
30	O'Donnell CJ and Nabel EG: Genomics of cardiovascular disease. N Engl J Med. 365:2098–2109. 2011. View Article : Google Scholar
31	De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C and Foti DP: Type 2 diabetes mellitus and cardiovascular disease: Genetic and epigenetic links. Front Endocrinol (Lausanne). 9(2)2018.PubMed/NCBI View Article : Google Scholar
32	Low Wang CC, Hess CN, Hiatt WR and Goldfine AB: Clinical update: Cardiovascular disease in diabetes mellitus: Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus-mechanisms, management, and clinical considerations. Circulation. 133:2459–2502. 2016.PubMed/NCBI View Article : Google Scholar
33	Williams SB, Cusco JA, Roddy MA, Johnstone MT and Creager MA: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 27:567–574. 1996.PubMed/NCBI View Article : Google Scholar
34	Demir B, Önal B, Özyazgan S, Kandaz C, Uzun H, Açıksarı G, Uygun T, Opan S, Karakaya O and Akkan AG: Does inflammation have a role in the pathogenesis of cardiac syndrome X? A genetic-based clinical study with assessment of multiple cytokine levels. Angiology. 67:355–363. 2016.PubMed/NCBI View Article : Google Scholar
35	Yan SF, Ramasamy R and Schmidt AM: Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl). 87:235–247. 2009.PubMed/NCBI View Article : Google Scholar
36	Li K, Zhao B, Dai D, Yao S, Liang W, Yao L and Yang Z: A functional p.82G>S polymorphism in the RAGE gene is associated with multiple sclerosis in the Chinese population. Mult Scler. 17:914–921. 2011.PubMed/NCBI View Article : Google Scholar
37	Kucukhuseyin O, Yilmaz-Aydogan H, Isbir CS and Isbir T: Is there any association between GLY82 ser polymorphism of rage gene and Turkish diabetic and non diabetic patients with coronary artery disease? Mol Biol Rep. 39:4423–4428. 2012.PubMed/NCBI View Article : Google Scholar
38	Li Y, Yang C, Ma G, Gu X, Chen M, Chen Y, Zhao B, Cui L and Li K: Association of polymorphisms of the receptor for advanced glycation end products gene with COPD in the Chinese population. DNA Cell Biol. 33:251–258. 2014.PubMed/NCBI View Article : Google Scholar
39	Cohen CR, Diel VB, La Porta VL, Rohde LE, Biolo A, Clausell N and Dos Santos KG: Association study of polymorphisms in the receptor for advanced glycation end-products (RAGE) gene with susceptibility and prognosis of heart failure. Gene. 510:7–13. 2012.PubMed/NCBI View Article : Google Scholar
40	Hooper J: Nurse education initiatives-making Project 2000 a reality. Managing the dynamic organisation. Nurse Educ Today. 10:380–384. 1990.PubMed/NCBI View Article : Google Scholar
41	Falcone C, Geroldi D, Buzzi MP, Emanuele E, Yilmaz Y, Fontana JM, Vignali L, Boiocchi C, Sbarsi I and Cuccia M: The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch Med Res. 39:320–325. 2008.PubMed/NCBI View Article : Google Scholar
42	Wang J, Zou L, Song Z, Lang X, Huang S, Lu F, Han L and Xu Z: Meta-analysis of RAGE gene polymorphism and coronary heart disease risk. PLoS One. 7(e50790)2012.PubMed/NCBI View Article : Google Scholar
43	Aydoğan HY, Küçükhüseyin O, Tekeli A and Isbir T: Associations of receptor for advanced glycation end products -374T/A and Gly82 Ser and peroxisome proliferator-activated receptor gamma Pro12Ala polymorphisms in Turkish coronary artery disease patients. Genet Test Mol Biomarkers. 16:134–137. 2012.PubMed/NCBI View Article : Google Scholar